Sales & Marketing Executing established pharma brand strategy: Key considerati... As blockbuster drug patents edge closer to expiry, pharma companies must rethink how they invest in, support, and scale established brands
News Novartis facing Gilenya generics again as Supreme Court lift... Novartis' hopes that the Supreme Court would protect its big-selling multiple sclerosis drug Gilenya from generic competition have been dashed.
Views & Analysis Increasing access to medicines: A critical look at pharmaceu... Extending patents is restricting patients’ access to the treatments they need.
News GSK sets up Nucala and Dupixent showdown in COPD GSK has said new data leads it to believe Nucala will be "highly competitive" with rival biologic Dupixent in COPD - if it gets approved by the FDA.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl